( Fendrich et al. 2009 , Falconi et al. 2016 , Howe et al. 2020 ). Systemic therapy for advanced and metastatic disease can consist of somatostatin analogs, peptide receptor radionuclide therapy (PRRT), molecular therapies targeting the mammalian
Search Results
Mojun Zhu, Karl R Sorenson, Rebecca Liu, Bonnie E Gould Rothberg, and Thorvardur R Halfdanarson
Maria Chiara Zatelli, Elia Guadagno, Erika Messina, Fabio Lo Calzo, Antongiulio Faggiano, Annamaria Colao, and NIKE Group
are no randomized studies indicating that platinum is the treatment of choice for these tumors. Thang and coworkers explored peptide receptor radionuclide therapy (PRRT) efficacy in G3 NEN, evaluated by response evaluation criteria in solid tumors
Johannes Hofland, Aura D Herrera-Martínez, Wouter T Zandee, and Wouter W de Herder
, Strosberg et al. 2017 b ) recommend SSAs as first-line therapy in CS in stage IV NET patients. Second-line options include IFN, locoregional therapy, SSA dose increase, everolimus or peptide receptor radionuclide therapy (PRRT) using radiolabeled SSAs
J R Strosberg, M Cives, J Hwang, T Weber, M Nickerson, C E Atreya, A Venook, R K Kelley, T Valone, B Morse, D Coppola, and E K Bergsland
radionuclide therapy (PRRT) vs octreotide 60mg long-acting repeatable (LAR) in patients with metastatic, progressive midgut NETs and demonstrated a 79% reduction in the risk for progression (HR=0.209, P <0.0001) ( Strosberg et al. 2015 ). Similarly, the
Clemens Kratochwil, Ruben López-Benítez, Walter Mier, Sabine Haufe, Berend Isermann, Hans-Ulrich Kauczor, Peter L Choyke, Uwe Haberkorn, and Frederik L Giesel
risk factors . European Journal of Nuclear Medicine and Molecular Imaging 35 1847 – 1856 . doi:10.1007/s00259-008-0778-1 . Bodei L Pepe G Paganelli G 2010 Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with
M Cives, M Ghayouri, B Morse, M Brelsford, M Black, A Rizzo, A Meeker, and J Strosberg
and radiosensitizing capecitabine), 11 had prior everolimus, 6 had prior sunitinib, 2 had prior peptide receptor radionuclide therapy (PRRT) and 9 had prior investigational agents (including pasireotide, bevacizumab and ganitumab). The median time from
Sten Myrehaug, David L Chan, Victor Rodriguez-Freixinos, Hans Chung, Julie Hallet, Calvin Law, Chirag Patel, Laurent Milot, John Hudson, Hanbo Chen, and Simron Singh
treatment with full protocol dose of 7.5 mg po daily everolimus. This full protocol dose of 7.5 mg was chosen extrapolating from the tolerability seen in a preceding trial of everolimus and peptide receptor radionuclide therapy (PRRT) ( Claringbold & Turner
David Taïeb, Christelle Fargette, Abhishek Jha, and Karel Pacak
option to beta emitters in peptide receptor radionuclide therapy (PRRT). In a recent study which included nine PPGL patients using actinium-225, partial response was observed in 50% of cases (objective response in 87.5%) ( Yadav et al. 2022 ). Seven out
Anna Angelousi, Aimee R Hayes, Eleftherios Chatzellis, Gregory A Kaltsas, and Ashley B Grossman
required to treat patients who fail to respond to TKIs or experience unacceptable toxicity. New-generation targeted therapies such as immunotherapy and peptide receptor radionuclide therapy (PRRT) may be promising but require prospective randomised trials
Joanna Grey and Kym Winter
. 2016 ); the use of peptide receptor radionuclide therapy (PRRT) using radiolabelled somatostatin analogues (Nbib1915485 ClinicalTrials.gov) and even immunotherapy (Nbib3072160 ClinicalTrials.gov). The emotional impact of pre-operative symptoms and
